Scarica l'app Stockscreener
86.97
0.49%
0.42
Dopo l'orario di chiusura:
86.98
0.01
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals stock hits 52-week high at 84.65 USD - Investing.com
Price to book forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR - TradingView
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy - Investing.com
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
ARWR Maintained by Chardan Capital -- Price Target Steady at $90 - GuruFocus
Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital - Moomoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development ProgramsSlideshow (NASDAQ:ARWR) 2026-06-30 - Seeking Alpha
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum - MSN
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from Russell 2000 Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals Inc R&D Webinar (Virtual) Transcript - GuruFocus
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Dynamic Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 3000E Value Benchmark - marketscreener.com
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ARWR) - TradingView
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (SWB:HDP1) - TradingView
HDP1 Forecast — Price Target — Prediction for 2027 - TradingView
A2AGYB Forecast — Price Target — Prediction for 2027 - TradingView
ARWR Forecast — Price Target — Prediction for 2027 - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com
Liquidity Mapping Around (ARWR) Price Events - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Leads Healthcare Stocks with St - GuruFocus
Arrowhead Pharmaceuticals gets EC approval for REDEMPLO in FCS - grafa.com
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP - GuruFocus
EU approves Arrowhead's REDEMPLO for rare fat disorder FCS - Stock Titan
The Insider Report: Stocks Celebrate Peace and a New Fed Chapter - Benzinga
Are Arrowhead Pharmaceuticals’ (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative? - Sahm
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update - Sahm
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars - Business Wire
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrowhead Pharmaceuticals Inc - TradingKey
Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals Rises as Recent Clinical Updates and EU Catalyst Keep Focus on Plozasiran - Quiver Quantitative
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 - Investing.com
ARWR Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership - Stock Titan
Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Institutional Confidence - TradingKey
Why (ARWR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
WEALTH EFFECTS LLC's Arrowhead Pharmaceuticals Inc(ARWR) Holding History - GuruFocus
Arrowhead Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):